Indole-3-carboxylic acid

产品说明书

Print
Chemical Structure| 771-50-6 同义名 : 3-吲哚甲酸 ;I3CA;ICOOH;β-Indolylcarboxylic Acid;Indole-β-carboxylic Acid
CAS号 : 771-50-6
货号 : A188858
分子式 : C9H7NO2
纯度 : 98%
分子量 : 161.16
MDL号 : MFCD00005624
存储条件:

Pure form Keep in dark place,Sealed in dry,Room Temperature

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(651.53 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Indole-3-carboxylic acid is a normal urinary indolic tryptophan metabolite and has been found elevated in patients with liver diseases[2]. A novel series of 1H-indole-3-carboxylic acid pyridine-3-ylamides were synthesized and identified to show high affinity and selectivity for 5-HT(2C) receptor. Among them, 1H-indole-3-carboxylic acid[6-(2-chloro-pyridin-3-yloxy)-pyridin-3-yl]-amide (15k) exhibits the highest affinity (IC50=0.5 nM) with an excellent selectivity (>2000 times) over other serotonin (5-HT(1A), 5-HT(2A), and 5-HT(6)) and dopamine (D(2)-D(4)) receptors[3]. After oral administration to mice, I3C (Indole-3-carbinol), in addition to its acid condensation products, is absorbed from the gut and distributed systemically into a number of well-perfused tissues, thus allowing the possibility for some pharmacological activity of the parent compound in vivo[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

6.21mL

1.24mL

0.62mL

31.03mL

6.21mL

3.10mL

62.05mL

12.41mL

6.21mL

参考文献

[2]Byrd DJ, Kochen W, Idzko D, Knorr E. The analysis of indolic tryptophan metabolites in human urine. Thin-layer chromatography and in situ quantitation. J Chromatogr. 1974 Jul 17;94(0):85-106

[3]Park CM, Kim SY, Park WK, Park NS, Seong CM. Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3844-7

[4]Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Lamb JH, Farmer PB, Steward WP, Williams ML. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res. 2004 Aug 1;10(15):5233-41